公司 A 股 2024 年半年度权益分派实施完毕后，本次以集中竞价交易方式回购 公司 A 股股份价格上限由不超过 89.71 元/股（含），调整为不超过 89.31 元/股（含）。 具体内容详见公司于 2024 年 10 月 11 日在上海证券交易所网站（www.sse.com.cn） 披露的《上海昊海生物科技股份有限公司关于 2024 年半年度权益分派实施后调整 回购 A 股股份价格上限的公告》（公告编号：2024-056）。 证券代码：688366 证券简称：昊海生科 公告编号：2025-019 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/8/17 | | --- | --- | | 回购方案实施期限 | 自第五届董事会第二十五次会议审议通过后 12 个 | | 月 | | | 预计回购金额 | 10,000.00万元~20,000.00万元 | | 回购用途 | □减少注册资 ...

上海昊海生物科技股份有限公司 证券代码：688366 证券简称：昊海生科 公告编号：2025-020 关于召开 2024 年度暨 2025 年第一季度中英双语 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （https://roadshow.sseinfo.com/activityDetails/33640）。 上海昊海生物科技股份有限公司（以下简称"公司"）已分别于 2025 年 3 月 22 日、2025 年 4 月 26 日发布公司 2024 年年度报告及 2025 年第一季度报告。 为便于广大投资者更全面深入地了解公司经营成果、创新亮点、财务状况、业务 规划及未来发展目标，公司将召开 2024 年度暨 2025 年第一季度中英双语业绩说 明会。 本次业绩说明会拟邀请全球投资者参与，旨在进一步深化境内外投资者对公 司的认知与理解。会议期间，参会人员可根据个人习惯，选择中文或英文进行交 流，本次活动将提供实时中英文字幕翻译服务。此次活动将采用直播和网络文字 互 动 的 方 式 举 行 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a total revenue of 621 million yuan in Q1 2025, a decrease of 4.44% year-on-year, with a net profit attributable to the parent company of 90 million yuan, down 7.41% [1]. - The ophthalmology business faced challenges due to price declines from centralized procurement, while the medical aesthetics sector continued to experience weak terminal consumption [2]. - The company is focused on R&D and innovation, with new products steadily advancing, including approvals for new intraocular lenses and the launch of the fourth-generation hyaluronic acid product "Hai Mei Yue Bai" [2]. - The gross profit margin slightly improved to 69.52% in Q1 2025, attributed to an increase in the proportion of high-margin medical aesthetics products [3]. - The company expects revenue growth to reach 3.103 billion yuan in 2025, with net profit projected at 489 million yuan, reflecting a compound annual growth rate of 16.42% from 2024 to 2025 [4][5]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 69.52%, with a net profit margin of 14.60% [3]. - The company reported a stable expense ratio of 51.79%, with sales expenses increasing slightly to 31.35% [3]. - The operating cash flow for Q1 2025 was 86 million yuan, indicating healthy cash flow management [3]. Product Development - The company is advancing its product pipeline, including new medical aesthetics products and intraocular lenses, which are expected to enhance market share [2]. - The innovative "Hai Mei Yue Bai" product is anticipated to address long-standing consumer issues related to hyaluronic acid retention [2]. Market Outlook - The report forecasts revenue growth for the company from 3.103 billion yuan in 2025 to 3.934 billion yuan in 2027, with a corresponding increase in net profit [4][5]. - The company is positioned to benefit from a recovery in the ophthalmology sector as product pipelines expand and centralized procurement impacts stabilize [4].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | H 股 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

2025年4月26日， 昊海生物发布了2024年年报。 # 财报数据 2024年公司实现营业 收入26.98亿元 ，同比 增长1.64% 。归属于母公司股东的净利润为4.20亿元，同比增 长1.04%。整体毛利率为69.88%，同比下降0.63个百分点。 费用变动 现金流 正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 昊海生物科技（股票代码：688366.SH / 06826.HK）成立于2007年1月24日，是一家专注于生物医用材料 研发、生产和销售的高科技生物医药企业。公司总部位于上海，注册资金1.2亿元人民币，主要从事生物材 料、生物制剂、基因工程药品的研发、生产和销售。 昊海生物科技的主营业务涵盖以下领域： 医疗美容与创面护理产品 公司是 国内第一 大手术防粘连剂生产商，2023年市场份额为28.82%，连续十七年稳居市场首位。 玻尿酸产品 ：公司是国内知名玻尿酸生产商之一，自主研发掌握了单相交联、低温二次交联、线性无颗 粒化交联以及有机交联等交联工艺。第一代产品"海薇"、第二代产品"姣兰"和第三代产品"海魅"已获得 市场广泛认可。 表皮修复基因工程制剂 ...

Core Insights - The medical aesthetics industry is experiencing significant revenue declines among major players, indicating a painful transformation phase for traditional companies [1][2][5] - Huaxi Biological, Aimeike, and Haohai Biological show varying degrees of revenue decline, highlighting differences in business structure and strategic deployment [1][2] - The industry is facing fundamental changes, raising concerns about which companies may fall behind in this transformation [1][8] Company Performance - Huaxi Biological reported a 20.77% year-on-year revenue decline in Q1 2025, with revenue shrinking to 1.078 billion yuan [1] - Aimeike's revenue decreased by 17.90% to 663 million yuan, while Haohai Biological's revenue fell by 4.25% to 619 million yuan [1] - Huaxi Biological's net profit plummeted from 961 million yuan in 2022 to 174 million yuan in 2024, with a further 58.13% decline in Q1 2025 [2][4] Strategic Adjustments - Huaxi Biological is undergoing a significant management overhaul, with leadership changes aimed at addressing operational challenges and improving performance [3][4] - The company is focusing on new fields such as glycoscience and cell biology, which has led to increased management costs [2][3] - Aimeike is shifting its strategy to accelerate product updates and pursue acquisitions in new areas like botulinum toxin and semaglutide [5][6] Market Dynamics - The medical aesthetics market is witnessing intense competition, particularly in the hyaluronic acid segment, raising concerns about whether the market has peaked [8][9] - New materials like hydroxyapatite and recombinant collagen are emerging as potential competitors to hyaluronic acid, indicating a shift in market dynamics [8][9] - Regulatory challenges and lengthy approval processes for medical products are significant barriers to industry growth, impacting companies' ability to innovate [9][10] Future Outlook - Huaxi Biological's turnaround efforts may take time to yield results, especially given its high marketing expenditures [10] - Aimeike's success will depend on the speed of product approvals and market acceptance of its diversified product strategy [6][10] - Haohai Biological is exploring new materials to drive growth, but its performance is still affected by pricing pressures from centralized procurement policies [7][10]

Financial Performance - The company reported total revenue of 619 million yuan for Q1 2025, a decrease of 4.25% year-on-year [1] - The net profit attributable to shareholders was 90.31 million yuan, down 7.41% compared to the same period last year [1] - The gross margin was 69.52%, an increase of 0.44% year-on-year, while the net profit margin decreased to 13.55%, down 5.36% [1] - Total expenses (selling, administrative, and financial) amounted to 272 million yuan, accounting for 43.96% of revenue, an increase of 5.94% year-on-year [1] - Earnings per share (EPS) was 0.39 yuan, a decrease of 7.14% year-on-year [1] Accounts Receivable and Cash Flow - Accounts receivable represented 77.11% of the latest annual net profit, indicating a significant amount of outstanding payments [1] - Operating cash flow per share was 0.37 yuan, down 18.22% year-on-year [1] Business Model and Market Position - The company's return on invested capital (ROIC) was 5.01%, indicating average capital returns [3] - The net profit margin for the previous year was 13.95%, suggesting high added value for products or services [3] - The company relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers [3] Future Expectations - Analysts expect the company's performance in 2025 to reach 505 million yuan, with an average EPS forecast of 2.17 yuan [4] Fund Holdings - The largest fund holding the company’s shares is Tianhong Pension 2035 Three-Year (FOF) A, with 12,400 shares newly entered into the top ten holdings [5] - The fund's current scale is 120 million yuan, with a net value of 1.0282 as of April 23, showing a 0.12% increase from the previous trading day [5] Product Performance - The company anticipates a 65% year-on-year increase in hyaluronic acid product sales in 2024, despite a slowdown in growth due to market conditions [7]

環境，社會 與管治報告 2024 | 目錄 | | | | --- | --- | --- | | | 關於本報告 | 2 | | | 關於本公司 | 4 | | | 年度主要榮譽及績效亮點 | 5 | | | ESG 管理 | | | | ESG 治理架構 | 8 | | 01 | 董事會聲明 | 8 | | | 利益相關方溝通 | 9 | | | 雙重重要性評估 | 10 | | | 合規運營 | | | | 風險管理與內部控制 | 13 | | 02 | 商業道德 信息安全與隱私保護 | 14 16 | | | 科技倫理 | 17 | | | 產品與創新 | | | | 研發創新 | 19 | | 03 | 知識產權保護 | 24 | | | 供應鏈安全 | 25 | | | 產品安全與質量 | 27 | | | 負責任營銷 | 31 | | | 環境保護 | | | | 應對氣候變化 | | | 04 | 環境管理體系 | 34 39 | | | 排污管理 | 39 | | | 資源管理與循環經濟 | 43 | | | 員工發展 | | | 05 | 招聘與發展 | 46 | | | 薪酬與福利 | ...